Abstracts Archive - Page 1764 of 2607 - ACR Meeting Abstracts

Abstract Number: 2478 • 2016 ACR/ARHP Annual Meeting
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 2479 • 2016 ACR/ARHP Annual Meeting
Work Productivity in Early Rheumatoid Arthritis Patients Treated before and after Implementation of a Treat-to-Target Strategy
Siri Lillegraven¹, Maria Dahl Mjaavatten¹, Nina P. Sundlisater¹, Anna-Birgitte Aga¹, Inge C Olsen², Till Uhlig¹, Daniel H. Solomon³, Tore K Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known cause of work productivity loss. Participation in work-related activities is defined as part of the primary goal of…
Abstract Number: 2480 • 2016 ACR/ARHP Annual Meeting
Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
SA Bergstra¹, CF Allaart¹, T Stijnen² and RBM Landewé^3,4, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Medical Statistics, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁴Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, there has been a trend to start methotrexate (MTX) in higher doses, either as monotherapy or in combination with other drugs in rheumatoid…
Abstract Number: 2481 • 2016 ACR/ARHP Annual Meeting
Infliximab Low Levels at Early Stages Predict the Loss of Drug Levels and the Clinical Response at One Year of Treatment in Patients with Rheumatoid Arthritis
Teresa Jurado¹, Chamaida Plasencia-Rodriguez², Ana Martínez³, Victoria Navarro-Compán⁴, Eva Olariaga-Merida⁵, Diana Peiteado⁶, Alejandro Villalba⁶, Gema Bonilla⁶, Cristina Diego⁷, Alejandro Balsa² and Dora Pascual-Salcedo⁸, ¹Immunology, University Hospital La Paz, Madrid, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁴Rheumatology, University Hospital La Paz, Madrid, Spain, ⁵Immunlogy, University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁷Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ⁸Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain
Background/Purpose: The anti-TNF monoclonal antibody Infliximab (Ifx), has proven effective in treating rheumatoid arthritis (RA), although in 40% of cases may fail, mainly due to…
Abstract Number: 2482 • 2016 ACR/ARHP Annual Meeting
Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
I.M Visman¹, MJ l'Ami², Gertjan Wolbink³ and Mike T. Nurmohamed^4,5, ¹Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are effective, safe and widely used treatment for rheumatoid arthritis (RA). The therapy is often started in combination…
Abstract Number: 2483 • 2016 ACR/ARHP Annual Meeting
Results of a Pilot Study of a Tailored Symptom Assessment Tool to Enhance Patient-Centered Care in Rheumatoid Arthritis: Choice RA
Jennifer Barton¹, Gina Evans-Young², Laura Trupin³, Allison Schue¹, Cornelia Ruland⁴ and Edward H. Yelin³, ¹VA Portland Health Care System, Portland, OR, ²Rheumatology, UCSF, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 2484 • 2016 ACR/ARHP Annual Meeting
Real World Treat to Target Strategy in Rheumatoid Arthritis: Radiograph and MRI Outcomes in Three Cohorts with 18 Month Follow up
Paul Bird¹, Maureen Rischmueller², Marie Feletar³, Gail Grant⁴, Margaret P. Staples⁵ and Stephen Hall⁶, ¹Medicine, University of New South Wales, Sydney, NSW, Australia, ²Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³Department of Epidemiology and Preventive Medicine, Monash University, Dandenong, Australia, ⁴Emeritus Research, Malvern East, Australia, ⁵Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Malvern, Australia, ⁶Cabrini Health and Monash University, Melbourne, VIC, Australia
Background/Purpose: The Treat to Target (TTT) model is well established in the treatment of rheumatic disease. Achieving DAS remission is one of the primary goals…
Abstract Number: 2485 • 2016 ACR/ARHP Annual Meeting
Correlates of Successful Flare Management: The Role of Clinician-Driven Treatment, Home-Based Strategies, and Medication Change
Taysir G. Mahmoud¹, M Frits², Christine Iannaccone³, Vivian P. Bykerk⁴, Clifton Bingham III⁵, Michael Weinblatt³ and N A Shadick², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Flares are a common experience in RA, often associated with worse clinical outcomes such as cardiovascular disease, lower functional status, and radiographic progression. …
Abstract Number: 2486 • 2016 ACR/ARHP Annual Meeting
Effect of a Dynamic Exercise Program in Combination with a Mediterranean Diet in Strength, Joint Mobility and Disease Activity in Women with Rheumatoid Arthritis
Juan Antonio Pineda-Juárez¹, Midori Ogata-Medel¹, Mariel Lozada-Mellado¹, Lilia Castillo-Martínez¹, Andrea Hinojosa-Azaola², Marco González-Contreras², Rocío Cervantes-Gaytán³, José Manuel García-Morales⁴, Jorge Alcocer-Varela⁵, Arturo Orea-Tejeda⁶ and Luis Llorente², ¹Clinical Nutrition Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Inmunology and Rheumatology Department-Physioterapy Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Inmunology and Rheumatology Department-Physiotherapy Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁶Cardiology Service, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation, joint pain, destruction of the synovial membranes and metabolic alterations due mainly by…
Abstract Number: 2487 • 2016 ACR/ARHP Annual Meeting
In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
Antonella Adinolfi¹, Giovanni Cagnotto², Filippo Luccioli³, Claudio Mastaglio⁴, Giulia Mirabelli³, Daniela Rossi⁵, Silvia Rossi², Emanuela Bellis⁶, Greta Carrara⁷, Carlo Alberto Scirè⁸, Annamaria Iagnocco⁹ and Garifallia Sakellariou², ¹Policlinico le Scotte, Siena, Italy, ²University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ³University of Perugia, Perugia, Italy, ⁴Moriggia-Pelascini, Gravedona, Italy, ⁵Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ⁶Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ⁹Sapienza University of Rome, Rome, Italy
Background/Purpose: Ultrasound (US) detected synovitis predicts flare in patients with rheumatoid arthritis (RA), while the role of tenosynovitis has yet to be established. The aim…
Abstract Number: 2488 • 2016 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis
Stephen Oakley^1,2, Gabor Major^3,4, David Mathers⁵, John van der Kallen⁶, Mark Collins⁷, Marc Toh⁸, Siva Ratnarajah⁸, Theo de Malmanche⁹ and Niloofar Esmaili¹⁰, ¹Rheumatology, Hunter New England Local Health District, New Lambton, Australia, ²School of Medicine & Public Health, University of Newcastle, Newcastle, Australia, ³Medicine, University of Newcastle, Newcastle, Australia, ⁴Rheumatology, Bone and Joint Institute, John Hunter Hospital NSW Australia, Newcastle, Australia, ⁵Rheumatology, Hunter New England Local Health District, Georgetown, Australia, ⁶Georgetown Arthritis, Georgetown, Australia, ⁷Private Practice, Broadmeadow, Australia, ⁸Rheumatology, Private Practice, Newcastle, Australia, ⁹Immunology, Hunter New England Local Health District, New Lambton, Australia, ¹⁰Rheumatology, Hunter New England Health, Newcastle, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) risk. The mechanisms of CV disease in RA remain poorly understood. Observational data suggest that…
Abstract Number: 2489 • 2016 ACR/ARHP Annual Meeting
Joint Damage Appears As Severe As Inflammation According to Physician Visual Analog Scales in Patients with Rheumatoid Arthritis Regardless of Disease Severity at 2 Sites, Which May Limit Results of a Treat-to-Target Strategy
Theodore Pincus¹, Isabel Castrejón¹, Kathryn Gibson² and Joel Block³, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Liverpool Hospital and University of New South Wales, Liverpool, Australia, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: A physician estimate of global status (DOCGL) on a 0-10 visual analog scale (VAS) was developed initially to assess inflammation in patients with rheumatoid…
Abstract Number: 2490 • 2016 ACR/ARHP Annual Meeting
Impact of Obesity Activity Indices and Therapeutic Dosage in Patients with Rheumatoid Arthritis in Dominican Republic
E Rodríguez-Bautista¹, V Rosario¹, R Peña-Blanco², R Munoz-Louis¹, Y Cruz-Rojas¹, I Paulino-Izquierdo¹, J Paula-Mateo¹, T Valdez-Lorie² and R Alba-Fériz¹, ¹Rheumatology, Hospital Docente Padre Billini (HDPB), Santo Domingo, Dominican Republic, ²Rheumatology, Hospital Docente Universitario Dr. Francisco E. Moscoso Puello (HFMP), Santo Domingo, Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic arthritis that mainly affects small and medium joints. It is the most common form…
Abstract Number: 2491 • 2016 ACR/ARHP Annual Meeting
Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Pascal Zufferey¹, Melanie Favre dit Jeanfavre², Alexandre Dumusc³, Charles Benaim⁴, Matthieu Perreau⁵ and Alexander K. So Sr.⁶, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, RHU/CHUV, Lausanne, Switzerland, ⁴DAL, MPR, Lausanne, Switzerland, ⁵Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁶Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: All biologic agents (bDMARDs) currently used in rheumatology can induce anti-drug antibodies (ADAB), which will influence the drug levels and the drug effectiveness. Why…
Abstract Number: 2492 • 2016 ACR/ARHP Annual Meeting
Mode of Administration in Rheumatoid Arthritis Treatments: An Exploration of Patient Preference for an ‘Ideal Treatment’
Peter C. Taylor¹, Rieke Alten², Juan Jesus Gomez-Reino³, Roberto Caporali⁴, Philippe Bertin⁵, Laura Grant⁶, Elaine Brohan⁶, Jane Wells⁶, Radu Vasilescu⁷ and Miriam Tarallo⁸, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Charité University Medicine, Berlin, Germany, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Università di Pavia, Pavia, Italy, ⁵Rheumatology, CHU Dupuytren, Limoges, France, ⁶Adelphi Values, Bollington, United Kingdom, ⁷Medical Affairs, Pfizer, Brussels, Belgium, ⁸GHV, Pfizer, Rome, Italy
Background/Purpose: The high prevalence and significant burden of RA has led to the development of a wide variety of treatments; specifically, conventional synthetic DMARDs, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].